TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - Shi, L. AU - Chen, S. AU - Yang, L. AU - Li, Y. PY - 2013 DA - 2013// TI - The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-74 DO - 10.1186/1756-8722-6-74 ID - Shi2013 ER - TY - JOUR AU - Han, E. Q. AU - Li, X. L. AU - Wang, C. R. AU - Li, T. F. AU - Han, S. Y. PY - 2013 DA - 2013// TI - Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-47 DO - 10.1186/1756-8722-6-47 ID - Han2013 ER - TY - JOUR AU - Li, Z. AU - Chen, L. AU - Rubinstein, M. P. PY - 2013 DA - 2013// TI - Cancer immunotherapy: are we there yet? JO - Exp Hematol Oncol VL - 2 UR - https://doi.org/10.1186/2162-3619-2-33 DO - 10.1186/2162-3619-2-33 ID - Li2013 ER - TY - JOUR AU - Ehrlich, D. AU - Wang, B. AU - Lu, W. AU - Dowling, P. AU - Yuan, R. PY - 2014 DA - 2014// TI - Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0091-3 DO - 10.1186/s13045-014-0091-3 ID - Ehrlich2014 ER - TY - JOUR AU - Goel, G. AU - Sun, W. PY - 2014 DA - 2014// TI - Cancer immunotherapy in clinical practice–the past, present, and future JO - Chin J Cancer VL - 33 UR - https://doi.org/10.5732/cjc.014.10123 DO - 10.5732/cjc.014.10123 ID - Goel2014 ER - TY - STD TI - Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513:202–209. ID - ref7 ER - TY - STD TI - Bang YJ, Chung HC, Shankaran V, Geva R, Catenacci DVT, Gupta S, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol 2015, 33(suppl):abstr 4001. ID - ref8 ER - TY - STD TI - Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Yuan S, Koshiji M, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. J Clin Oncol 2015, 33(suppl):abstr 4010. ID - ref9 ER - TY - JOUR AU - Smyrk, T. C. AU - Watson, P. AU - Kaul, K. AU - Lynch, H. T. PY - 2001 DA - 2001// TI - Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma JO - Cancer VL - 91 UR - https://doi.org/3.0.CO;2-U DO - 3.0.CO;2-U ID - Smyrk2001 ER - TY - JOUR AU - Llosa, N. J. AU - Cruise, M. AU - Tam, A. AU - Wicks, E. C. AU - Hechenbleikner, E. M. AU - Taube, J. M. AU - Blosser, R. L. AU - Fan, H. AU - Wang, H. AU - Luber, B. S. PY - 2015 DA - 2015// TI - The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-14-0863 DO - 10.1158/2159-8290.CD-14-0863 ID - Llosa2015 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. AU - Skora, A. D. AU - Luber, B. S. AU - Azad, N. S. AU - Laheru, D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - STD TI - El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo W, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015, 33(suppl):abstr LBA101. ID - ref13 ER - TY - JOUR AU - Goel, G. AU - Sun, W. PY - 2015 DA - 2015// TI - Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0141-5 DO - 10.1186/s13045-015-0141-5 ID - Goel2015 ER - TY - JOUR AU - Beatty, G. L. AU - Chiorean, E. G. AU - Fishman, M. P. AU - Saboury, B. AU - Teitelbaum, U. R. AU - Sun, W. AU - Huhn, R. D. AU - Song, W. AU - Li, D. AU - Sharp, L. L. PY - 2011 DA - 2011// TI - CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans JO - Science VL - 331 UR - https://doi.org/10.1126/science.1198443 DO - 10.1126/science.1198443 ID - Beatty2011 ER - TY - JOUR AU - Royal, R. E. AU - Levy, C. AU - Turner, K. AU - Mathur, A. AU - Hughes, M. AU - Kammula, U. S. AU - Sherry, R. M. AU - Topalian, S. L. AU - Yang, J. C. AU - Lowy, I. AU - Rosenberg, S. A. PY - 2010 DA - 2010// TI - Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma JO - J Immunother VL - 33 UR - https://doi.org/10.1097/CJI.0b013e3181eec14c DO - 10.1097/CJI.0b013e3181eec14c ID - Royal2010 ER - TY - JOUR AU - Smith, A. D. AU - Roda, D. AU - Yap, T. A. PY - 2014 DA - 2014// TI - Strategies for modern biomarker and drug development in oncology JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0070-8 DO - 10.1186/s13045-014-0070-8 ID - Smith2014 ER - TY - JOUR AU - Mahoney, K. M. AU - Atkins, M. B. PY - 2014 DA - 2014// TI - Prognostic and predictive markers for the new immunotherapies JO - Oncology (Williston Park) VL - 28 ID - Mahoney2014 ER -